oral semaglutide novo novonordisk has received European Commission approval for Wegovy® pill, the European Union's first GLP-1 receptor agonist for chronic weight management. The once-daily oral is approved for adults with obesity or The Ozempic Pill Has Arrived.

Avoid excessive moisture

It works as a single GLP-1 receptor agonist and activates GLP-1 receptors in both the gut and the brain

Interestingly, these drugs also have a major benefit on cardiovascular disease outcomes and are approved to reduce major adverse cardiovascular events in type 2 DM patients with CV disease and independently in heart failure patients

Therapy should therefore not be discontinued in patients with established CVD who do not achieve the weight-loss targets observed in clinical trials

Fiber supplementation is one of the safest long-term supplement strategies available

FDAs 2026 assessment found insufficient clinical safety information and insufficient evidence to establish effectiveness